Global Search | Novartis

Hide Filters

Showing 2683 results

Press Release / Sep 06, 2019

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

Currently, there are no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a particularly aggressive form of the diseaseBreakthrough Therapy…
Press Release / Sep 05, 2019

Novartis study shows migraine support in the workplace can improve employee quality of life

Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1] …
Press Release / Sep 09, 2019

Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine

The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
Press Release / Sep 12, 2019

New Novartis data show Mayzent® can help preserve mobility for longer in patients with secondary progressive multiple sclerosis (SPMS)

New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent® (siponimod) can help patients keep their mobility for over four years longer on average *[1] …
Press Release / Sep 10, 2019

Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent…
Press Release / Sep 13, 2019

Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
Press Release / Sep 13, 2019

New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians New data show how the use of two central nervous system-derived…
Key Release / Sep 17, 2019

Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
Press Release / Sep 19, 2019

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
Press Release / Sep 18, 2019

Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin

Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…